Labcorp Holdings Inc.
LH · NYSE
Company research
Labcorp Holdings Inc. (NYSE: LH) is one of the world's largest independent clinical laboratory networks, headquartered in Burlington, North Carolina, and serving clients across approximately 100 countries. The company operates through two primary segments — Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) — performing more than 700 million tests annually spanning routine blood work, oncology, genetic diagnostics, infectious disease, and personalized medicine. Its Biopharma Laboratory Services segment supports pharmaceutical, biotechnology, and medical device companies through drug development, preclinical research, clinical trials, and post-approval studies, with involvement in approximately 75% of FDA-approved drugs in 2024. Under the leadership of CEO Adam H. Schechter, Labcorp employs nearly 70,000 people worldwide, generates approximately $13–14 billion in annual revenue, and holds a market capitalization of approximately $22.7 billion.
Research reports
TickerNerd · June 14, 2026LH Stock Forecast 2026 - LabCorp Price Targets & Predictions
Synthesizes Wall Street analyst views on LH, highlighting a bullish consensus with a Strong Buy-style rating, a median 12‑month price target of 320 (270–340 range) and roughly 20% implied upside, while reminding investors that these forecasts are speculative and should be weighed against individual risk tolerance.
ClearThesis.ai · May 27, 2026LH Stock Analysis 2026: Is Labcorp a Buy? Moat, Valuation & ForecastFrames Labcorp as a “defensive compounder” benefiting from 7% annual revenue growth, roughly 1.2 billion in free cash flow and a strategic focus on specialized diagnostics and hospital lab management, arguing the market underestimates its ability to consolidate a fragmented industry while warning that Medicare reimbursement cuts or hospital contract losses could break the thesis.
Blank Capital Research · March 16, 2026LABCORP HOLDINGS INC. (LH) Stock Analysis — March 2026 Rating, Price, and ForecastAssigns LH a quantitative Hold rating with a composite score of 54.1/100, noting attractive valuation versus healthcare peers (discounted P/E, P/B and P/S multiples), adequate margins and low‑beta stability but elevated leverage and only middling momentum and quality scores, leading to a balanced risk‑reward view rather than a clear buy or sell call.
Artificall · February 23, 2026Is Labcorp Holdings a Turnaround Bet? A 2026 Moat ReviewProvides a moat‑focused review of Labcorp’s business model and financials, highlighting steady revenue growth, improving margins, safe Altman Z‑score and bullish 12‑month share price performance, but emphasizing declining ROIC, moderate leverage, and sector and regulatory pressures; it concludes that LH is a moderately profitable, stable long‑term holding that merits a cautious, value‑oriented approach rather than aggressive buying.